280 related articles for article (PubMed ID: 32512655)
21. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
[TBL] [Abstract][Full Text] [Related]
24. Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Steinhardt MJ; Zhou X; Krummenast F; Meckel K; Nickel K; Böckle D; Messerschmidt J; Knorz S; Dierks A; Heidemeier A; Lapa C; Einsele H; Rasche L; Kortüm KM
Int J Immunopathol Pharmacol; 2020; 34():2058738420980258. PubMed ID: 33353443
[TBL] [Abstract][Full Text] [Related]
25. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Duman BB; Sahin B; Ergin M; Guvenc B
Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
28. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
29. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Minarik J; Novak M; Flodr P; Balcarkova J; Mlynarcikova M; Krhovska P; Pika T; Pikalova Z; Bacovsky J; Scudla V
Eur J Haematol; 2017 Aug; 99(2):186-189. PubMed ID: 28470777
[TBL] [Abstract][Full Text] [Related]
30. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Development of CD38-Targeted [
Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
33. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.
Qing M; Zhou T; Perova T; Abraham Y; Sweeney C; Krevvata M; Zhang X; Qi M; Gao G; Kim TM; Yao M; Cho SG; Eom HS; Lim ST; Yeh SP; Kwong YL; Yoon DH; Kim JS; Kim WS; Zhou L; Attar R; Verona RI
Ann Hematol; 2024 Jun; 103(6):1989-2001. PubMed ID: 38233570
[TBL] [Abstract][Full Text] [Related]
34. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
36. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
37. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
[TBL] [Abstract][Full Text] [Related]
38. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
39. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
40. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]